Medincell gains 3% on the presentation by its partner Teva of new positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia.

"These data demonstrate, across several baseline indicators, a significant improvement in social interactions and quality of life between baseline and week eight of the study", says the biopharmaceutical company.

"The data show that Medincell's subcutaneous administration technology used for olanzapine LAI has not resulted in any post-injection delirium/sedation syndrome (PDSS) events to date", it continues.

Copyright (c) 2024 CercleFinance.com. All rights reserved.